Radius Health, Inc. (NASDAQ:RDUS) insider Jesper Hoiland acquired 6,800 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The shares were acquired at an average cost of $29.04 per share, with a total value of $197,472.00. Following the transaction, the insider now directly owns 12,900 shares in the company, valued at approximately $374,616. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jesper Hoiland also recently made the following trade(s):

  • On Friday, September 15th, Jesper Hoiland acquired 6,100 shares of Radius Health stock. The shares were acquired at an average cost of $32.72 per share, with a total value of $199,592.00.

Radius Health, Inc. (RDUS) opened at $28.75 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87. Radius Health, Inc. has a 1-year low of $27.16 and a 1-year high of $55.97.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same period last year, the firm earned ($1.07) EPS. equities research analysts anticipate that Radius Health, Inc. will post -5.41 EPS for the current fiscal year.

WARNING: “Jesper Hoiland Acquires 6,800 Shares of Radius Health, Inc. (RDUS) Stock” was posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.watchlistnews.com/jesper-hoiland-acquires-6800-shares-of-radius-health-inc-rdus-stock/1690248.html.

Several large investors have recently modified their holdings of RDUS. BlackRock Inc. boosted its holdings in shares of Radius Health by 98,245.6% during the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock worth $101,679,000 after acquiring an additional 2,628,070 shares during the period. Farallon Capital Management LLC raised its position in shares of Radius Health by 18.3% in the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after buying an additional 569,300 shares in the last quarter. TimesSquare Capital Management LLC acquired a new stake in shares of Radius Health in the second quarter valued at approximately $25,589,000. BB Biotech AG raised its position in shares of Radius Health by 11.0% in the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after buying an additional 498,400 shares in the last quarter. Finally, RA Capital Management LLC acquired a new stake in shares of Radius Health in the second quarter valued at approximately $22,486,000.

RDUS has been the subject of several recent research reports. Canaccord Genuity set a $85.00 price target on Radius Health and gave the company a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald set a $58.00 target price on Radius Health and gave the stock a “buy” rating in a report on Sunday, July 23rd. BidaskClub cut Radius Health from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Jefferies Group LLC restated a “hold” rating and set a $38.00 price target (up from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $51.00.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Insider Buying and Selling by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.